The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

Two biotech companies failed to reverse an order barring them from selling biosimilars of Regeneron’s eye disease drug Eylea ...

The Federal Circuit left in place a pair of orders blocking two competitors of Regeneron Pharmaceuticals Inc. from marketing ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged at ...

Eylea (aflibercept) is a prescription drug that treats certain eye conditions. Eylea can cause side effects that range from mild to serious. An example includes cataracts, which may become a long ...

Results from a trial comparing three treatments for serious eye disease have shown that Regeneron and Bayer's Eylea is the most effective. The trial was sponsored by the US government-funded ...

San Francisco, California-- (Newsfile Corp. - January 30, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct ...

Earlier on Monday, Regeneron shared preliminary results from the fourth quarter that showed Eylea HD generated just $305 million in the U.S. It was a stunning drop-off from the $392 million the ...